Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: Bhag Karamchandani who wrote (4525)	6/18/1998 12:41:00 AM
From: scaram(o)uche	Respond to of 6136

Bhag: I was surprised by the wording with respect to the 47 patients. It would have been nice to know if the number of patients/group was approximately equal. If the frequency of stabilization was higher in the 5 mg group than in the 50 or 100 mg group, say 3 of 5 versus 2 of 10 or something similar, then it would raise some eyebrows. While the groups are small and these are patients with advanced cancers, it would have been nice to see an indication of "dose response". The mention of the third generation MMPIs?? I have mentioned, on several occasions, that we need to keep an eye on Chiroscience and their claims. Your concern could be, IMO, well-founded. On the other hand, the spectrum of enzymes that are inhibited by 3340 may be just what certain patients need. Time on the learning curve, to prevent blindsides, is valuable. I was therefore pleased to see reference to the next generation molecules. The ambiguity bugs me too. Rick